Dongyao Pharmaceutical-B: Fu Shan has been transferred from non-executive director to executive director
Dongyao Pharmaceutical-B announced that Mr. Fu Shan will be transferred from non-executive director to executive director starting from October 11, 2025, responsible for leading the group's management and development. Dr. Liu Jun resigned from his positions as executive director and CEO for personal reasons, and Ms. Huang Chunying also resigned from her positions as non-executive director and vice chairman. Mr. Fu will succeed Dr. Liu as the company's authorized representative, with the appointment effective from October 11, 2025
According to the announcement from Dongyao Pharmaceutical-B (01875), Mr. Fu Shan will be transferred from the company's non-executive director to executive director starting from October 11, 2025, and will be responsible for leading and supervising the management and development of the group. After the transfer, Mr. Fu will continue to serve as the chairman of the company, chairman of the nomination committee, and chairman of the strategic and ESG committee.
The changes in the positions of directors and chief executive officer will take effect from October 11, 2025: (i) Dr. Liu Jun resigned as the company's executive director, chief executive officer, chief scientific officer, and member of the strategic and ESG committee for personal reasons; and (ii) Ms. Huang Chunying resigned as the company's non-executive director, vice chairman, and member of the strategic and ESG committee for personal reasons. In addition, Dr. Liu and Ms. Huang will also resign from all director and (if applicable) executive positions in all subsidiaries of the company.
Following Dr. Liu's departure from the board, Mr. Fu has been appointed as the company's authorized representative to replace Dr. Liu in accordance with the provisions of Listing Rule 3.05, with effect from October 11, 2025
